RT
Rubik Therapeutics
Rubik Therapeutics develops targeted cancer therapies, including CAR-T, radioligand, and ADC treatments, by leveraging highly selective tumor-specific targets identified through genomic dysregulation. The company utilizes its proprietary Oncolinkage platform to optimize these targets for best-in-class selectivity across multiple therapeutic modalities. This approach yields partner-ready programs focused on advancing precision oncology treatments for significant patient populations.
- Biotechnology
Updated 23 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Rubik Therapeutics develops targeted cancer therapies, including CAR-T, radioligand, and ADC treatments, by leveraging highly selective tumor-specific targets identified through genomic dysregulation. The company utilizes its proprietary Oncolinkage platform to optimize these targets for best-in-class selectivity across multiple therapeutic modalities. This approach yields partner-ready programs focused on advancing precision oncology treatments for significant patient populations.